Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00388609 · ClinicalTrials.gov registry record · Phase 2
Multiple-dose Study to Evaluate the Efficacy, Safety and Pharmacokinetics of BMS-646256 in Obese Subjects
A Phase 2 study, sponsored by Bristol-Myers Squibb.
- Terminated
- Registry status
- Phase 2
- Development phase
- 705
- Enrollment target
NCT00388609 is a Phase 2 study that was terminated before completion, run by Bristol-Myers Squibb. The registered enrollment target is 705 participants.
The verdict
NCT00388609, a Phase 2 study, was terminated before completion, sponsored by Bristol-Myers Squibb.
- TERMINATED
- Registry status
- Phase 2
- Development phase
- 705 participants
- Enrollment target
Study Summary
The purpose of this study is to learn if BMS-646256 can cause weight loss in men and women who are: * overweight with high blood pressure or high cholesterol or * obese The safety of this treatment will also be studied
Interventions
- DRUG Placebo
- DRUG BMS-646256
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 705 participants |
| Start Date | 2006-11 |
| Est. Completion | 2009-04 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT00388609
The ClinicalTrials.gov registry entry for NCT00388609 describes a study currently listed as terminated, categorized as Phase 2. The registered enrollment target is 705 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Bristol-Myers Squibb, which has 1,025 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 2 interventions - of which Placebo is the first listed.
NCT00388609 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT00388609 about?
NCT00388609 is a clinical study titled "Multiple-dose Study to Evaluate the Efficacy, Safety and Pharmacokinetics of BMS-646256 in Obese Subjects". The purpose of this study is to learn if BMS-646256 can cause weight loss in men and women who are: * overweight with high blood pressure or high cholesterol or * obese The safety of this treatment will also be studied
What is the current status of trial NCT00388609?
This trial is currently terminated. It is a Phase 2 study. The enrollment target is 705 participants. The study started on 2006-11. Estimated completion is 2009-04.
What interventions are being tested in trial NCT00388609?
The interventions under investigation include: Placebo (DRUG), BMS-646256 (DRUG).
Who is sponsoring clinical trial NCT00388609?
This trial is sponsored by Bristol-Myers Squibb, which has 1,025 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.